Hi, Interestingly, in previous years (27th Feb -2015) there was...

Hi,

Interestingly, in previous years (27^th Feb -2015) there was a ‘half year commentary’ release too that accompanied the HY results. This is also referenced in Page 1 of this year’s HY report where it says: “Please refer to the half-year commentary for an explanation of the results.” I’m guessing there should still be commentary to come?

They did make small mention infection control in the 3^rd paragraph in section ‘(b) operational results’:

“In the short term the Company will continue to search for new product opportunities, especially in the area of infection control as well as opportunities to strengthen its off-shore presence. Directors and management reaffirm the Company’s commitment to providing excellent quality products to its human health customers on a timely basis and at acceptable gross margins to the Company.”

I agree on your assessment of Medivet, quite pleased they made the tough decision and I believe they will be all the better for it in the coming HY. The declining margins is interesting, hard to tell whether that’s a combo of squeeze in winning contracts and more competitive pricing to increase sales or fully attributable to the manufacturing side and decline in the FX rate. I’d still like to see chunkier sales ‘wins’ announced to market like other medical manufacturers tend to do (ie ACG, UCM etc), I think this provides holders with a bit more info to work on throughout the quarter and demonstrate solid behind the scene action.

Will await the HY commentary and meanwhile review the numbers in more depth.

DYOR, IMO etc…